Molecular regulation of cellular immunity by FOXP3

Advances in Experimental Medicine and Biology

Volumn 665, Issue , 2009, Pages 30-35

  McMurchy, Alicia N ^a   Di Nunzio, Sara ^a   Roncarolo, Maria Grazia ^a   Bacchetta, Rosa ^a   Levings, Megan K ^a  

^a Department of Surgery ^*

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYCLOSPORIN A; HISTONE DEACETYLASE; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 9; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; ISOPROTEIN; METHOTREXATE; RAPAMYCIN; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; RITUXIMAB; STEROID; T LYMPHOCYTE RECEPTOR; TACROLIMUS; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ARTICLE; AUTOIMMUNITY; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOKINE PRODUCTION; CYTOLOGY; DISEASE CONTROL; DRUG MEGADOSE; EPIGENETICS; GENE CONTROL; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IPEX SYNDROME; MOLECULAR BIOLOGY; NONHUMAN; OLIGOMERIZATION; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH17 CELL; UNSPECIFIED SIDE EFFECT; PHYSIOLOGY; REVIEW;

FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, CELLULAR;

EID: 77952500003     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1599-3_3     Document Type: Article

References (144)

1. Allan SE, Broady R, Gregori S, et al. CD4+ T-regulatory cells: Toward therapy for human diseases. Irnmunol Rev 2008; 223:391-421. (Pubitemid 351986179)
2. Miyara M, Sakaguchi S. Natural regulatory T-cdls: Mechanisms of suppression. Trends Mol Med 2007; 13(3):108-116. (Pubitemid 46341958)
3. van Maurik A, Herber M, Wood KJ, et al. Cutting edge: CD4+CD25+ alloanngen-specific immunoregulatory cells that can prevent CD8+ Tvcell-mediared grafi: Rejection : Implications for anti-CD I54 immunotherapy. J Irnmunol 2002; 169(10):5401-5404. (Pubitemid 35291635)
4. Lin CY, Graca L, Cobbold SP, et al. Dominant transplantation tolerance impairs CD8+ T-cell function but not expansion. Nat Irnmunol 2002; 3(12) :1208-1213. (Pubitemid 35469706)
5. Lim HW; Hillsamer P, Banham AH, et al. Cutting edge: Direct suppression of B-ceUs by CD4+ CD25+ regulator y T-ceUs. J lrnmuno12005; 175(7):4180-4183.
6. Maloy KJ. Antonelli LR. Lefevre.M., et al. Cure of innate intestinal immune pathology by CD4+CD25+ regulatory Tvcells, Immunol Lett 2005: 97(2) :189-192. (Pubitemid 40326950)
7. Tiemessen MM. Jagget al, Evans HG, et al. CD4+CD25+Foxp3+ regulatory Tvcells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 2007: 104(49):19446-19451.
8. Chen GY, Chen C. Wang L, et al. Cutting edge: Broad expression of the FoxP3 locus in epithelial cells: A caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressingcells.J Immunol 2008: 180(8):5163-5166.
9. Zuo T, Wang L, Morrison C, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007: 129(7):1275-1286. (Pubitemid 46970708)
10. Brunkow ME. Jeffery EW; Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein. scurfin, results in the fatallymphoproliferative disorder of the scurfy mouse. Nat Genet 2001: 27(1):68-73. (Pubitemid 32044521)
11. Bennett CL. Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy. X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27(1) :20-21. (Pubitemid 32044513)
12. Wildin RS. Ramsdell F,PeakeJ, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001: 27(1) :18-20. (Pubitemid 32044512)
13. Godfrey VL. Wilkinson JE, RussellLB. X-linked Iymphoreticular disease in the scurfy (sf) mutant mouse. AmJ Patho11991 ; 138(6):1379-1387.
14. Schubert LA, Jeffery E, Zhang Y, et al. Scurfin (FOXP3) acts as a repressor of transcription and regulates T-cell acnvanon.J BioI Chern 2001; 276(40) :37672-37679.
15. Wu Y, Borde M, Heissmeyer V, et al. FOXP3 controls regulatory T'cell function through cooperation with NFAT. Cell 2006: 126(2):375-387. (Pubitemid 44092960)
16. Marson A. Kretschmer K, Frampton GM, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007: 445(7130):931-935.
17. Zheng Y,Josefowicz SZ. Kas A., et al. Genome-wide analysisof Foxp3 target genes in developing and mature regulatory T-cells. Nature 2007: 445(7130):936-940.
18. Ziegler SF. FOXP3 : Of mice and men. Annu Rev Immunol2006; 24:209-226.
19. Li B, Samanta A. Song X, et al. FOXP3 ensembles in T-cell regulation. Immunol Rev 2006; 212:99-113 (Pubitemid 44116703)
20. Li B. Greene MI. FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle 2007: 6(12) :1432-1436.
21. LopesJE. Torgerson TR, Schubert LA, et al. Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor.J Immunol 2006; 177(5):3133-3142. (Pubitemid 44277831)
22. Li B, Samanta A. Song X, et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA 2007: 104(11):4571-4576. (Pubitemid 47186266)
23. Chae WJ. Henegariu O. Lee SK, et al. The mutant leucine-zipper domain impairs both dimerization and suppressive function of Foxp3 in T-cells. Proc Natl Acad Sci USA 2006: 103(25):9631-9636. (Pubitemid 43955876)
24. Li B, Samanta A, Song X, et al. FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. Int Immunol 2007; 19(7):825-835. (Pubitemid 47241891)
25. Khattri R, Cox T, Yasayko SA, et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol2003: 4(4) :337-342. (Pubitemid 36432315)
26. Hori S, Nomura T, Sakaguchi S. Control of regulatory 'l-cell development by the transcription factor Foxp3. Science 2003: 299(5609) :1057-1061. (Pubitemid 36222930)
27. Fontenot JD. Gavin MA, Rudensky AY. Foxp3 programs the development and function ofCD4+CD25+ regulatory T-cells. Nat Immunol2003; 4(4):330-336. (Pubitemid 36432314)
28. Sakaguchi S. Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated Tvcells expressing lL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J Immunol1995: 155(3):1151-1164.
29. Suri-Payer E, Amar AZ. Thornton AM, et al. CD4+CD25+ 'l-cells inhibit both the induction and effector function of autoreacrive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998; 160(3) :1212-1218. (Pubitemid 28093417)
30. Maynard CL, Harrington LE.JanowskiKM, et al. Regulatory T-cells expressinginterleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat Immunol2007; 8(9):931-941. (Pubitemid 47300007)
31. Lin W; Haribhai D, Reiland LM, et al. Regulatory T-cell development in the absence of functional Foxp3. Nat Immunol 2007; 8(4) :359-368. (Pubitemid 46745411)
32. Wan YY,FlavellRA. Identifying Foxp3-expressingsuppressor T-cells with a bicistronic reporter. Proc Natl Acad Sci USA 2005: 102(14):5126-5131.
33. Sakaguchi S. Naturally arising Foxp3-expressingCD25+CD4+ regulatory T-cells in immunological tolerance to self and nonself Nat Immunol 2005: 6(4) :345-352. (Pubitemid 41716771)
34. Shevach EM. From vanilla to 28 flavors: Multiple varieties of T regulatory cells. Immunity 2006: 25(2) :195-201. (Pubitemid 44224153)
35. Levings MK. Sangregorio R. Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T-cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193(11):1295-1302.
36. Dieckmann D. Plottner H. Berchtold S, et al. Ex vivo isolation and characterization of CD4(+)CD25(+) T-cells with regulatory properties from human blood. J Exp Med 2001; 193(11):1303-1310. (Pubitemid 32524780)
37. Jonuleit H. Schmitt E. Stassen M, et al. Identification and functional characterization of human CD4(+)CD25(+) T-cells with regulatory properties isolated from peripheral blood. J Exp Med 200 1; 193(11):1285-1294. (Pubitemid 32524778)
38. Thornton AM. ShevachEM. CD4+CD25+ immunoregulatory T-cells suppress polyclonal T-cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188(2):287-296. (Pubitemid 28357757)
39. Takahashi T. KuniyasuY. Toda M, et al. Immunologic self- tolerancemaintained by CD25+CD4+ naturally anergic and suppressive T-cells: Induction of autoimmune disease by breaking their anergic/ suppressive state. Int Immunol1998; 10(12):1969-1980. (Pubitemid 28566059)
40. Collison LW;Workman CJ. Kuo IT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450(7169):566-569. (Pubitemid 350190247)
41. Niedbala W; Wei XQ. Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T-cells and suppression of Th17 cells. Eur J Immunol 2007; 37(11) :3021-3029. (Pubitemid 350131282)
42. Sakaguchi S. Ono M. Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T-cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212:8-27. (Pubitemid 44116697)
43. Lan RY, Ansari AA. Lian ZX, et al. Regulatory T-cells: Development, function and role in autoimmunity. Autoimmun Rev 2005; 4(6) :351-363. (Pubitemid 41080072)
44. Mays LE, Chen YH. Maintaining immunological tolerance with Foxp3. Cell Res 2007; 17(11):904-918. (Pubitemid 350126862)
45. Liu W; Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.J Exp Med 2006; 203(7) :1701-1711. (Pubitemid 44036276)
46. Seddiki N. Santner-Nanan B, Marrinson Jet al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T-cells. J Exp Med 2006; 203(7) :1693-1700. (Pubitemid 44036275)
47. Yamaguchi T. Hirota K, Nagahama K, et al. Control of immune responses by antigen-specific regulatory T-cells expressing the folate receptor. Immunity 2007; 27(1) :145-159. (Pubitemid 47089022)
48. Bruder D, Probst-Kepper M, Westendorf AM, et al. Neuropilin-l : A surface marker of regulatory T-cells. Eur J Immunol2004; 34(3):623-630. (Pubitemid 39255909)
49. Vignali DA. Collison LW. Workman CJ. How regulatory T-cells work Nat Rev Immunol 2008 ; 8(7) :523-532.
50. Yi H, Zhen Y,Jiang L, et al. The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T-cells. Cell Mol Immunol2006; 3(3):189-195.
51. Banham AH. Powrie FM, Suri-Payer E. FOXP3+ regulatory T-cells: Current controversies and future perspectives. Eur J Immunol 2006; 36(11):2832-2836. (Pubitemid 44782555)
52. Tang Q. Henriksen KJ. Bi M, et al. In vitro-expanded antigen-specific regulatory T-cells suppress autoimmune diabetes. J Exp Med 2004; 199(11):1455-1465. (Pubitemid 38780401)
53. Motter C. UhligHH. Powrie F.Cutting edge: Cure of colitis by CD4+CD25+ regulatoryT-cells.J Immunol 2003; 170(8):3939-3943. (Pubitemid 36428153)
54. Taylor PA. Lees CJ, Blazar BR. The infusion ofex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits grafi-versus-host disease lethality. Blood 2002; 99(10):3493-3499. (Pubitemid 34534513)
55. Hoffmann P, Ermann J, Edinger M, et al. Donor-type CD4(+)CD25(+) regulatory 'l-cells suppress lethal acute grafi-versus-host disease afiet allogeneic bone marrow transplantation. J Exp Med 2002; 196(3):389-399 (Pubitemid 34875667)
56. Xia G, He J. Zhang Z, et al. Targeting acute allografi rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T-cells. Transplantation 2006; 82(12) :1749-1755. (Pubitemid 46043197)
57. Graca L, Le Moine A. Lin CY, et al. Donor-specific transplantation tolerance: The paradoxical behavior of CD4+CD25+ T-cells. Proc Nad Acad Sci USA 2004; 101(27):10122-10126. (Pubitemid 38891205)
58. Viglietta V, Baecher-AllanC.Weiner HL, et al. Lossof function al suppression by CD4+CD25+ regulatory T-cells in patients with multiple sclerosis. J Exp Med 2004; 199(7):971-979. (Pubitemid 38481088)
59. KriegelMA. Lohmann T. Gabler C, et al. Defective suppressor function of human CD4+ CD25+ regulatory T-cells in autoimmune polyglandular syndrome type II. J Exp Med 2004; 199(9):1285-1291. (Pubitemid 38620265)
60. Huan J, Culbertson N, Spencer L, et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005; 81(1):45-52. (Pubitemid 41139109)
61. Offner H, VandenbarkAA. Congruent effectsof estrogen and T-cell receptor peptide therapy on regulatory T-cells in EAE and MS. Int Rev Inununo12005; 24(5-6) :447-477. (Pubitemid 41755156)
62. Venken K, Hellings N. Hensen K, et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006; 83(8) :1432-1446. (Pubitemid 43844989)
63. Takahashi M, Nakamura K, HondaK ecaL An inverse correlation of humanperipheral blood regulatory T-cellfrequency with the disease activity of ulcerative colitis. Dig Dis Sci2006: 51(4):677-686.
64. Kawai T, CosimiAB,Spitzer TR, et al. Hl.Amismarched renaltransplantation without maintenance immunosuppression. N Engl J Med 2008: 358(4):353-361. (Pubitemid 351159234)
65. MarrinL, Funes de la Vega M, Bocrie O, et al. Detectionof Foxp3+ cells on biopsies of kidney transplants with early acuterejection. Transplant Proc 2007: 39(8):2586-2588. (Pubitemid 47588396)
66. LathropSK, Santacruz NA, PhamD, et al. Antigen-specific peripheral shaping of the natural regulatory T-cellpopulation. J ExpMed2008: 205(13):3105-3117.
67. Hsieh CS, LiangY,TyznikAJet al. Recognition of the peripheral selfby naturally arising CD25+ CD4+ T-cell receptors. Immunity 2004: 21(2):267-277. (Pubitemid 39094055)
68. JordanMS,Boesteanu A, Reed AJet al.Thymic selection of CD4+CD25+ regulatory T-cells inducedby an agonist self-peptide. Nat Immunol2001:2(4):301- 306. (Pubitemid 33706340)
69. Kretschmer K, Apostolou I, Hawiger D, et al. Inducing and expanding regulatory T-cell populations by foreign antigen. Nat Immunol2005: 6(12):1219-1227. (Pubitemid 43045633)
70. Gavin MA, Rasmussen JP, Fontenot JD, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature2007: 445(7129):771-775. (Pubitemid 46279714)
71. Hill JA, Feuerer M, TashK, et al. Foxp3 transcription-factor-dependent and -independenr regulation of the regulatory T-cell transcriptional signature. Immunity 2007: 27(5):786-800. (Pubitemid 350110546)
72. ZhengSG, WangJH, Stohl.W., et al., TGF-beta requires CTLA-4 early afi:er T-cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol 2006: 176(6):3321-3329. (Pubitemid 43363978)
73. Chen W; Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T-cells to CD4+CD25+ regulatory T-cells byTGF-betainductionof transcription factorFoxp3. J ExpMed2003: 198(12):1875-1886. (Pubitemid 38032120)
74. Fantini MC, Becker C, Monteleone G, et al. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T-cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004: 172(9):5149-5153. (Pubitemid 38542009)
75. Andersson J, Tran DQ, PesuM, et al. CD4+ FoxP3+ regulatory T-cells confer infectious tolerance in a TGF-beta-dependent manner. J ExpMed 2008; 205(9):1975-1981.
76. Hum EN, Punkosdy GA, Glass DD, et al. TGF-beta-induced Foxp3+ regulatory T-cells rescue scurfy mice. EurJ Inununol2008; 38(7):1814-1821.
77. Hum EN, Stummvoll GH, DiPaolo RJecal.Cuttingedge: Antigen-specific TGF beta-induced regulatory T-cells suppress Thl7-mediated autoimmune disease. J Immunol 2008: 181(12):8209-8213.
78. Coombes JL, Siddiqui KR, Arancibia-Carcamo CVet al.Afunctionally specialized population of mucosal CDI03+ DCs induces Foxp3+ regulatory T-cells viaa TGF-betaand retinoic acid-dependent mechanism. JExpMed 2007; 204(8):1757-1764. (Pubitemid 47236314)
79. Benson MJ, Pino-Lagos K, Rosemblatt M., et al., All-trans retinoic acid mediates enhanced T reg cell growth, differentiation and gut homing in the face of high levels of costimulation. J Exp Med 2007: 204(8):1765-1774. (Pubitemid 47236315)
80. SunCM, HallJA, BlankRBet al.Small intestine lamina propriadendritic cells promotede novogeneration of Foxp3 T regcells via retinoic acid. J ExpMed 2007: 204(8):1775-1785. (Pubitemid 47236316)
81. Mucida D, ParkY,Kim Get al. Reciprocal TH 17and regulatory T'celldifferentiation mediated by retinoic acid. Science 2007; 317(5835):256-260. (Pubitemid 47076203)
82. Liu Y, Zhang P, Li J, et al. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T-cells. Nat Inununo12008: 9(6):632-640. (Pubitemid 351712634)
83. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T-cells. PLoS Bioi 2007: 5(2):e38.
84. Shevach EM,Davidson TS,Hum EN, et al. Role ofTGF-Beta in the induction of Foxp3 expression and T regulatory cellfunction. J Clin Immunol 2008: 28(6):640-646.
85. Chai JG, Xue SA, Coe D, et al. Regulatory T-cells, derived from naive CD4+CD25- T-cells by in vitro Foxp3 genetransfer, can induce transplantation tolerance. Transplantation 2005; 79(10):1310-1316. (Pubitemid 40734792)
86. AllanSE,Passerini L, Bacchetta Ret al.Theroleof2 FOXP3isoforms in the generation of humanCD4+ Tregs. J Clin Invest 2005; 115(11):3276-3284. (Pubitemid 41567592)
87. AllanSE,Alsrad AN, Merindol N, et al. Generation of potent and stable humanCD4+ T regulatory cells byactivation-independent expression of FOXP3. Mol Ther 2008: 16(1):194-202.
88. Ziegler SF. FOXP3: Not JUSt for regulatory T-cells anymore. EurJ Inununol 2007; 37(1):21-23. (Pubitemid 46128782)
89. Allan SE, Song-Zhao GX, Abraham T, et al. Inducible reprogramming of humanT-cells intO Tregcells by a conditionally active formof FOXP3. EurJ Inununo12008: 38(12):3282-3289.
90. WanIT, Flavell RA.Regulatory T-cellfunctions are subverted and converted owingto attenuated Foxp3 expression. Nature2007: 445(7129):766-770. (Pubitemid 46279706)
91. Andersen KG, Butcher T, Betz AG. Specific immunosuppression withinducible Foxp3-rransduced polycIonal T-cells. PLoSBioi2008: 6(11):e276.
92. Morgan ME, van Bilsen JH, Bakker AM, et al. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol 2005; 66(1) :13-20. (Pubitemid 40037706)
93. Tran DQ, Ramsey H, ShevachEM. Induction ofFOXP3 expression in naive human CD4+FOXP3 T-cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007; 110(8):2983-2990. (Pubitemid 350006952)
94. Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cyrokine production. Int Imrnunol 2007; 19(4):345-354. (Pubitemid 46523383)
95. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T-cells: FOXP3 expression without regulatory T-cell development. Proc Nad Acad Sci USA 2006; 103(17):6659-6664.
96. Wang J, Ioan-Facsinay A, van der Voort EI, et al. Transient expression of FOXP3 in human activated nonregulatory CD4+ T-cells. Eur J Immunol2007; 37(1) :129-138. (Pubitemid 46128793)
97. Pillai V. Ortega SB, Wang CK, et al. Transient regulatory T-cells: A state attained by all activated human T-cells. Clin Immunol2007; 123(1):18-29. (Pubitemid 46401504)
98. WalkerMR, Kasprowicz DJ, Gersuk VH, et al. Induction of FoxP3 and acquisition ofT regulatory activity by stimulated human CD4+CD25- T-cells. J Clin Invest 2003; 112(9):1437-1443. (Pubitemid 38057697)
99. Levings MK, Gregori S, Tresoldi, et al. Differentiation of Ttl cells by immature dendritic cells requires IL-I0 but not CD25+CD4+ Tr cells. Blood 2005; 105(3):1162-1169. (Pubitemid 40170889)
100. Charila TA, Blaeser F, Ho N, et al. JM2, encoding a fork head-related protein , is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000; 106(12) :R75-81. (Pubitemid 32038594)
101. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: Forkhead box protein 3 mutations and lack of regulatory T-cells. J Allergy Clin Immunol 2007; 120(4):744-750; quiz 751-742. (Pubitemid 47531861)
102. Gambineri E, Perroni L, PasseriniL, et al. Clinical and molecular profile ofa new series ofpatients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: Inconsistent correlation between forkhead box prote in 3 expression and disease severity. J Allergy Clin Immunol 2008; 122(6):1105-1112 ell01.
103. YongPL, Russo P, Sullivan KE. Use of sirolimus in IPEX and IPEX-like children J Clin Immunol 2008; 28(5) :581-587.
104. Bindl L, Torgerson T, Perroni L, et al. Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinoparhy, enteropathy, X-linked syndrome) J Pediatr 2005; 147(2) :256-259. (Pubitemid 41207844)
105. Battaglia M, Stabilini A, Migliavacca B, et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T-cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177(12):8338-8347. (Pubitemid 44893795)
106. Coenen JJ, Koenen HJ, van RijssenE, et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T-cells. Bone Marrow Transplant 2007; 39(9):537-545. (Pubitemid 46629589)
107. Rao A, Kamani N, Filipovich A, et al. Successful bone marrow transplantation for IPEX syndrome afier reduced-intensity conditioning. Blood 2007; 109(1):383-385. (Pubitemid 46053081)
108. Bacchetta R, Passerini L, Gambineri E, et al. Defective regulatory and effector T-cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116(6):1713-1722.
109. Manavalan JS, Kim-Schulze S, Scotto Let al. A1loantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ rolerogenic endothelial cells, inhib iting alloreacrivity, Inr Immunol 2004; 16(8):1055-1068.
110. Smith EL, Finney HM, Nesbitt AM, et al. Splice variants of human FOXP3 are functional inhibitors of human CD4+ T-cell activation. Immunology 2006; 119(2):203-211. (Pubitemid 44401639)
111. Du J, Huang C, Zhou B, et al. Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3. J Immunol 2008; 180(7) :4785-4792
112. Krejsgaard T, Gjerdrum LM, Ralfkiaer E, et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome. Leukemia 2008; 22(12) :2230-2239.
113. Macian F. NFAT proteins : Key regulators of T-cell development and function Nat Rev Immunol 2005; 5(6) :472-484. (Pubitemid 40835035)
114. Rao A, Luo C.Hogan PG. Transcription factors of the NFAT family: Regulation and function Annu Rev Immunol1997; 15:707-747. (Pubitemid 27169297)
115. Bertelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T-cells and NF-kappa B to repress cytokine gene expression and effector function s of T helper cells. Proc Nad Acad Sci USA 2005; 102(14):5138-5143.
116. Macian F,Garcia-Cozar F,Im SH, et al. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002; 109(6):719-731. (Pubitemid 34722268)
117. Lee SM, Gao B, Fang D. FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1. Blood 2008; 111(7):3599-3606.
118. Derijard B. HibiM. WuI.H, et al..JNKl : A protein kinase stimulated byUV light and Ha-Ras that binds and phosphorylaees the c-Jun activation domain. Cell 1994; 76(6):1025-1037. (Pubitemid 24106383)
119. SuB. Jacinto E, HibiMet al.JNK is involved in signal integration duringcostimulation ofT-lymphocytes. Cell 1994; 77(5):727-736. (Pubitemid 24175608)
120. Kwon HK. SoJS, LeeCG, et al. Foxp3 induces IL-4 genesilencing by affecting nuclear translocation of NFkappaB and chromatin structure. Mol Immunol2008; 45(11):3205-3212.
121. OnoM. Yaguchi H. OhkuraN, et al. Foxp3 controls regulatory Tcell function byinteracting withAMLl/ Runx1. Nature2007;446(7136):685-689. (Pubitemid 46606883)
122. ZhangF,MengG. Strober W.Interactions among the transcription factors Rnnxl, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T-cells. Nat Immunol 2008; 9(11):1297-1306.
123. Yang XO. Nurieva R, Martinez GJ, et al. Molecular antagonismand plasticity of regulatory and inflammatory T-cell programs. Immunity 2008; 29(1):44-56.
124. Zhou L. Lopes JE. ChongMM, et al. TGF-beta-induced Foxp3 inhibitsT(H)17 celldifferentiation by antagonizing RORgammat function. Nature2008; 453(7192):236-240. (Pubitemid 351667978)
125. Samanta A. Li B, SongX, et al. TGF-beta and IL-6 signals modulate chromatin bindingand promoter occupancy by acetylated FOXP3. ProcNatlAcad SciUSA2008; 105(37):14023-14027.
126. Tao R, de Zoeten EF. Ozkaynak E, et al. Deacetylase inhibitionpromotes the generation and function of regulatory T-cells. Nat Med2007; 13(11):1299-1307. (Pubitemid 350073591)
127. Kouzarides T. Chromatinmodifications and their function. Cell 2007; 128(4):693-705.
128. Chen C, Rowell EA, Thomas RM, et al. Transcriptional regulation by Foxp3 is associated with direct promoteroccupancy and modulation of histoneacetylation. J BioiChern2006; 281(48):36828-36834. (Pubitemid 46042151)
129. Haxhinasto S. Mathis D. Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J ExpMed 2008; 205(3):565-574. (Pubitemid 351439304)
130. Sauer S, Bruno L. Herrweck A, et al. T-cell receptor signaling controls Foxp3 expression via PI3K, Akt and mTOR. ProcNatlAcad SciUSA2008; 105(22):7797-7802. (Pubitemid 351872718)
131. ZeiserR. Negrin RS. Interleukin-2 receptordownstream events in regulatory T-cells: Implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008; 7(4):458-462.
132. WuestTY,Willette-Brown J, Durum SKet al. The Influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T-ceUs. J Leukoc Bioi 2008; 84(4):973-980.
133. Passerini L, Allan SE,Battaglia M, et al. STAT5-signaling cytokines regulate the expression of FOXP3in CD4+CD25+ regulatory T-cells and CD4+CD25- effector T-cells. Int Immunol2008; 20(3):421-431.
134. HuehnJ, Polansky JK. HamannA. Epigenetic controlof FOXP3expression: The key to a stable regulatory T-celllineage? Nat Rev Immunol2009; 9(2):83-89.
135. Janson PC. Winerdal ME. Marits P, et al. FOXP3 promoterdemethylation reveals the committedTreg population in humans. PLoS ONE 2008; 3(2):e1612.
136. Mantel PY, OuakedN. Ruckert Bet al. Molecular mechanisms underlying FOXP3inductionin human TceUs. J Immunol2006; 176(6):3593-3602. (Pubitemid 43364007)
137. Nagar M, Vernitsky H. Cohen Y, et al. Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD25-CD4+ Tvcells. Ine Immunol 2008; 20(8):1041-1055.
138. Polansky JK, Kretschmer K. Freyer J, et al..DNA methylation controls Foxp3 geneexpression. EurJ Immunol 2008; 38(6):1654-1663.
139. Dong C. TH17 cells in development: An updatedviewof their molecular identityand genetic programming. Nat RevImmunol 2008; 8(5):337-348. (Pubitemid 351595217)
140. Bettelli E, Oukka M. Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Irnmunol2007; 8(4):345-350. (Pubitemid 46745409)
141. Lochner M. PedutoL. CherrierM, et al. In vivo equilibrium of proinAammatory IL-17+ and regulatory IL-I0+ Foxp3+ RORgamma t+ T-cells. J Exp Med 2008; 205(6):1381-1393.
142. Xu L, Kitani A, Fuss I, et al. Cutting edge: Regulatory T-cells induce CD4+CD25-Foxp3- 'f-cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol 2007; 178(11):6725-6729. (Pubitemid 46847395)
143. Radhakrishnan S. Cabrera R, Schenk ELet al. Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol 2008; 181(5):3137-3147.
144. Koenen HJ. Smeets RL. Vink PM, et al. Human CD25highFoxp3pos regulatory T-cells differentiate into IL-17 producingcells. Blood2008; Sep 15;112(6):2340-52.